[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-03-21-10":3},{"date":4,"filings":5,"has_more":207,"limit":208,"page":209,"total_count":210},"2026-03-21",[6,14,18,25,29,36,40,44,51,55,63,70,74,78,83,87,91,96,100,104,109,113,117,123,127,131,138,143,147,151,156,160,164,169,173,179,184,188,192,199,203],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Zydus Lifesciences Ltd","2026-03-21T08:15:52.832000","BSE","Launches Semaglutide in India with Innovative Reusable Pen","69bff35d955551b9b1c3303e","ZYDUSLIFE","*   Announced the launch of Semaglutide Injection (brands: SEMAGLYN™, MASHEMA™, ALTERME™) for Type 2 Diabetes and Obesity in India, following patent expiry.\n*   The product will be delivered via an innovative, reusable multi-dose pen, for which the company holds exclusive rights, aiming to improve patient convenience and lower therapy costs.\n*   The average monthly cost is stated to be approximately Rs. 2,200, positioning it as a significantly lower-cost alternative to capture market share.\n*   \u003Cb>Key Red Flag:\u003C\u002Fb> The filing is dated March 21, 2026, a future date that is highly unusual and may be a typographical error requiring investor clarification.",{"company_name":7,"filing_date":8,"filing_source":9,"headline":15,"id":16,"stock_code":12,"summary_text":17},"Zydus Launches Semaglutide in India with Innovative Reusable Pen","69bff36714f116b023204fbe","*   **Product Launch:** The company has launched Semaglutide Injection in India for the treatment of Type 2 Diabetes and Obesity.\n*   **Key Innovation:** The drug is delivered via an exclusive, reusable multi-dose pen, designed to improve patient convenience and significantly lower the overall cost of therapy.\n*   **Strategic Entry:** The launch is timed with the patent expiry of Semaglutide, positioning Zydus to capture a share of the high-growth anti-diabetic and anti-obesity market.\n*   **Cost Advantage:** The company states the average monthly cost of treatment will be approximately Rs. 2,200, making it a more affordable option for patients.\n*   **Regulatory Approval:** The product has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing.",{"company_name":19,"filing_date":20,"filing_source":9,"headline":21,"id":22,"stock_code":23,"summary_text":24},"Delhivery Ltd","2026-03-21T08:06:07.599000","NCLT Approves Merger of Subsidiaries with Delhivery","69bff351cd586b864dc7b90b","DELHIVERY","• **Merger Approved:** The National Company Law Tribunal (NCLT) has sanctioned the scheme to merge two wholly-owned subsidiaries, Spoton Logistics and Spoton Supply Chain, into Delhivery.\n• **Key Date:** The \"Appointed Date\" for the amalgamation, from which all assets and liabilities are transferred, is April 1, 2025.\n• **No Shareholder Dilution:** No new shares will be issued by Delhivery as part of the merger, meaning no change in the shareholding pattern.\n• **Financial Impact:** Delhivery will absorb Spoton Logistics, which has negative reserves of ₹12.04 crore, to be adjusted against its own reserves.\n• **Key Risks Noted:** The filing discloses a pending complaint with the Registrar of Companies (RoC) regarding customer data leakage and an ongoing tax appeal for one of the merging entities.",{"company_name":19,"filing_date":20,"filing_source":9,"headline":26,"id":27,"stock_code":23,"summary_text":28},"NCLT Approves Merger of Spoton Subsidiaries with Delhivery","69bff35ccd947ce0af599900","*   The National Company Law Tribunal (NCLT) has approved the merger of two wholly-owned subsidiaries, Spoton Logistics Pvt. Ltd. and Spoton Supply Chain Solutions Pvt. Ltd., into Delhivery Ltd.\n*   The Appointed Date for the amalgamation is set for April 1, 2025.\n*   No new shares will be issued as part of the merger, meaning there will be no change in the shareholding pattern or equity dilution for Delhivery shareholders.\n*   The primary goal is to streamline the corporate structure, enhance operational efficiency, and achieve cost savings.\n*   **Key Risk:** A complaint is pending with the Registrar of Companies (ROC) against Delhivery, alleging customer data leakage and harassment. The company has filed a reply.",{"company_name":30,"filing_date":31,"filing_source":9,"headline":32,"id":33,"stock_code":34,"summary_text":35},"Dr Reddys Laboratories Ltd","2026-03-21T07:32:45.005000","Dr. Reddy's Launches Obeda®, India's First Generic Semaglutide for Diabetes","69bff33030cad470bb204f49","DRREDDY","• **Product Launch:** Announced the launch of 'Obeda®', the first Drugs Controller General of India (DCGI)-approved generic Semaglutide injection for managing Type 2 Diabetes.\n• **First-Mover Advantage:** Marks a \"Day-1 entry\" into the high-growth GLP-1 therapy market, targeting a large patient population in India.\n• **In-House Capability:** The entire product, including the active ingredient (API) and formulation, was developed and manufactured in-house, demonstrating strong R&D and operational strength.\n• **Pricing & Format:** The product will be available as a user-friendly, pre-filled weekly pen, with a patient cost of ₹ 4,200 per month.\n• **Strategic Outlook:** The company plans to build a full portfolio of GLP-1 therapies and launch generic semaglutide in several other countries.",{"company_name":30,"filing_date":31,"filing_source":9,"headline":37,"id":38,"stock_code":34,"summary_text":39},"Dr. Reddy's Launches 'Obeda®', India's First Generic Semaglutide","69bff35fb9faa4a752c33046","• **Product Launch:** Announced the launch of 'Obeda®', India's first Drugs Controller General of India (DCGI)-approved generic Semaglutide injection for Type 2 Diabetes.\n• **Strategic Entry:** Marks a significant day-1 entry into the high-growth GLP-1 market upon patent expiry, providing a potential first-mover advantage in India.\n• **Pricing & Format:** The product will be available as a user-friendly, pre-filled pen, costing the patient ₹ 4,200 per month.\n• **In-House Capability:** The entire product, from API to formulation, was developed and manufactured in-house, highlighting the company's vertical integration.\n• **Patient Support:** A comprehensive patient support program named \"SemaKare™\" will be launched to assist with onboarding and therapy adherence.\n• **Market Expansion:** The company plans to introduce generic semaglutide in \"several countries\" as part of its phase-1 launch.",{"company_name":30,"filing_date":31,"filing_source":9,"headline":41,"id":42,"stock_code":34,"summary_text":43},"Dr. Reddy's Launches 'Obeda®', India's First Generic Semaglutide for Diabetes","69bff35f13f0bdde015998a6","*   Announced the launch of 'Obeda®', the first Drugs Controller General of India (DCGI)-approved generic Semaglutide injection for Type 2 Diabetes.\n*   The product is priced at ₹ 4,200 per month, aiming to make the advanced therapy more affordable in a market with over 101 million adults with diabetes.\n*   The launch is backed by a successful Phase-III clinical study that demonstrated non-inferior efficacy and a similar safety profile compared to the innovator drug.\n*   This marks the company's strategic entry into the high-growth GLP-1 therapy space, with plans to build a full portfolio and expand the product's availability to other countries.",{"company_name":45,"filing_date":46,"filing_source":9,"headline":47,"id":48,"stock_code":49,"summary_text":50},"Radhagobind Commercial Ltd","2026-03-21T05:36:01.483000","Insolvency Update: Key Creditors' Meeting Scheduled","69bff324b9faa4a752c33044","539673","*   The company is currently under the Corporate Insolvency Resolution Process (CIRP), indicating severe financial distress.\n*   The 5th meeting of the Committee of Creditors (COC) is scheduled for February 5, 2026, to discuss the progress of the insolvency proceedings.\n*   Key agenda items include the need for interim finance to fund the resolution process, highlighting a significant liquidity risk.\n*   Shareholders face a very high risk of total equity value erosion as the company's future is dependent on a resolution plan being approved by creditors.",{"company_name":45,"filing_date":46,"filing_source":9,"headline":52,"id":53,"stock_code":49,"summary_text":54},"Insolvency Meeting Notice Reveals Major Discrepancies","69bff35106cfb807e9c7b944","*   The company, currently under Corporate Insolvency Resolution Process (CIRP), filed a notice for its 5th Committee of Creditors (CoC) meeting.\n*   \u003Cb>RED FLAG:\u003C\u002Fb> The notice for the meeting held on Feb 5, 2026, was filed significantly late on March 21, 2026, a compliance breach.\n*   \u003Cb>MAJOR RED FLAG:\u003C\u002Fb> The agenda for the February meeting contains a chronological impossibility, referring to events from March 17, 2026, raising serious concerns about the filing's accuracy.\n*   The company is seeking interim finance from creditors to cover insolvency costs, highlighting severe financial distress.\n*   Due to the insolvency, there is a very high risk of complete erosion of value for equity shareholders.",{"company_name":56,"filing_date":57,"filing_source":58,"headline":59,"id":60,"stock_code":61,"summary_text":62},"Lemon Tree Hotels Limited","2026-03-21T02:12:21.774000","NSE","Director Resignation Announced with Unusual Future Dates","69bff31b06cfb807e9c7b93d","LEMONTREE","• Freyan Jamshed Desai has resigned from the position of Non-Executive Non-Independent Director.\n• The effective date of the resignation is listed as March 20, 2026.\n• **Red Flag:** The filing and resignation dates are set in the future, which is highly unusual and likely a data entry error.",{"company_name":64,"filing_date":65,"filing_source":58,"headline":66,"id":67,"stock_code":68,"summary_text":69},"Poonawalla Fincorp Limited","2026-03-21T01:35:18.660000","CRISIL Reaffirms Top 'AAA\u002FStable' Rating, Citing Strong Promoter Support","69bff302e2d5e830b1c7b96f","POONAWALLA","*   \u003Cb>Top Ratings Reaffirmed:\u003C\u002Fb> CRISIL has reaffirmed its highest long-term rating of 'CRISIL AAA\u002FStable' and short-term rating of 'CRISIL A1+', indicating a very strong degree of safety for financial obligations.\n*   \u003Cb>Key Drivers:\u003C\u002Fb> The rating is underpinned by strong promoter support from the Cyrus Poonawalla group, healthy capitalisation (Capital Adequacy Ratio at 18.17%), and a diversified, low-cost funding profile.\n*   \u003Cb>Strong Performance:\u003C\u002Fb> The company reported a significant turnaround with a Net Profit of ₹287 crore in 9M FY26 and rapid AUM growth of ~73% (annualized) to ₹55,017 crore.\n*   \u003Cb>New Bond Rating:\u003C\u002Fb> A 'CRISIL AA+\u002FStable' rating was assigned to the company's new Perpetual Bonds worth ₹1,500 crore.\n*   \u003Cb>Risks to Watch:\u003C\u002Fb> Key risks highlighted by CRISIL include the lack of seasoning in the fast-growing loan book and the need to sustain profitability amidst expansion costs.",{"company_name":64,"filing_date":65,"filing_source":58,"headline":71,"id":72,"stock_code":68,"summary_text":73},"CRISIL Reaffirms 'AAA\u002FStable' Rating, Cites Strong Promoter Support","69bff325cd947ce0af5998fe","- CRISIL has reaffirmed the company's highest long-term rating of `CRISIL AAA\u002FStable` and short-term rating of `CRISIL A1+`, citing strong strategic and financial support from the Poonawalla promoter group.\n- A new rating of `CRISIL AA+\u002FStable` has been assigned to the proposed ₹1,500 Crore Perpetual Bonds, enabling a new capital raise.\n- The company reported a strong turnaround with a Profit After Tax of ₹287 Crore for the first nine months of FY26, driven by rapid AUM growth of ~73% (annualized).\n- Key risks highlighted by the rating agency include the lack of seasoning in the rapidly grown loan book and the need to monitor the sustainability of the earnings profile amid expansion.",{"company_name":64,"filing_date":65,"filing_source":58,"headline":75,"id":76,"stock_code":68,"summary_text":77},"CRISIL Reaffirms Top 'AAA\u002FStable' Rating, Cites Strong Growth & Promoter Backing","69bff331c1595024c2c33011","*   CRISIL has reaffirmed its highest long-term rating of `CRISIL AAA\u002FStable` on the company's bank facilities and most debt instruments, and assigned a `CRISIL AA+\u002FStable` rating to new Perpetual Bonds worth ₹1,500 Crore.\n*   The rating is driven by strong promoter support from the Poonawalla group, healthy capitalization (CAR at 18.17%), and significant AUM growth to ₹55,017 crore as of Dec-25.\n*   Key risks highlighted are the lack of seasoning in the rapidly growing loan book and the potential impact of expansion costs (400 new branches planned) on near-term profitability.\n*   **Red Flag:** The entire filing is dated March 20, 2026, and references future financial periods (FY25, FY26), indicating a likely major typographical error in the document's year.",{"company_name":64,"filing_date":79,"filing_source":58,"headline":80,"id":81,"stock_code":68,"summary_text":82},"2026-03-21T01:35:18.561000","CARE Reaffirms 'AAA' Rating with Stable Outlook","69bff2f230cad470bb204f47","*   CARE Ratings has reaffirmed its highest 'CARE AAA; Stable' rating on the company's long-term bank facilities and debt, citing strong promoter support from the Cyrus Poonawalla group.\n*   Assets Under Management (AUM) showed strong growth, reaching ₹55,017 crore as of December 31, 2025.\n*   A net loss of ₹98 crore was reported for FY25, primarily due to the absence of exceptional gains from a subsidiary sale that had boosted FY24 profits.\n*   Asset quality is improving, with Gross NPA at 1.51% after a temporary spike in Q2FY25 caused by a legacy loan book.\n*   The company received a ₹1,500 crore equity infusion from its promoters in September 2025, strengthening its capital position.",{"company_name":64,"filing_date":79,"filing_source":58,"headline":84,"id":85,"stock_code":68,"summary_text":86},"CARE Ratings Reaffirms Top-Tier 'AAA' Rating with Stable Outlook","69bff326955551b9b1c3303c","*   CARE Ratings has reaffirmed the company's long-term rating at 'CARE AAA; Stable', signifying the highest degree of safety. A new Perpetual Debt instrument of ₹1,500 Cr was assigned a 'CARE AA+; Stable' rating.\n*   The rating is driven by strong promoter support from the Cyrus Poonawalla group (which recently infused ₹1,500 Cr), healthy capitalization, and a strong liquidity position.\n*   Under new MD & CEO Arvind Kapil, the company is targeting 5x-6x AUM growth over the next five years, focusing on a diversified retail and MSME portfolio.\n*   Key monitorables include managing asset quality as the company scales (a past spike in NPAs was noted and addressed). The filing also contained highly unusual futuristic dates (2025\u002F2026).",{"company_name":64,"filing_date":79,"filing_source":58,"headline":88,"id":89,"stock_code":68,"summary_text":90},"CARE Reaffirms Top-Tier 'AAA' Rating Amidst Ambitious Growth","69bff32a14f116b023204fa4","*   CARE Ratings has reaffirmed the company's highest credit rating of 'CARE AAA; Stable' on its long-term bank facilities and NCDs, citing strong promoter support and healthy financial flexibility.\n*   Assets Under Management (AUM) showed robust growth, more than doubling from ₹25,003 Cr in FY24 to ₹55,017 Cr as of Dec 2025.\n*   Despite strong growth, the company reported a net loss of ₹98 Crore in FY25, a sharp contrast to the ₹2,056 Crore profit in FY24, though profitability has since recovered in the current fiscal year.\n*   Promoters infused ₹1,500 Crore in Sep 2025, signaling strong commitment. The company aims for a 5x-6x AUM growth over the next five years under its new MD & CEO, Mr. Arvind Kapil.",{"company_name":64,"filing_date":92,"filing_source":58,"headline":93,"id":94,"stock_code":68,"summary_text":95},"2026-03-21T00:52:11.676000","CRISIL Reaffirms Top 'AAA' Rating; New Perpetual Bonds Rated 'AA+'","69bff2ee955551b9b1c33039","*   CRISIL has reaffirmed its highest rating of 'CRISIL AAA\u002FStable' on the company's long-term bank facilities and NCDs, and 'CRISIL A1+' on its short-term instruments.\n*   A new rating of 'CRISIL AA+\u002FStable' has been assigned to the company's Perpetual Bonds worth ₹1,500 Crore, facilitating future capital raising.\n*   The rating is driven by strong promoter support from the Cyrus Poonawalla group, healthy capitalization (CAR at 18.17%), and a significant turnaround to profitability.\n*   🔴 \u003Cb>CRITICAL RED FLAG:\u003C\u002Fb> The filing is dated for the future (March 20, 2026) and uses future financial data (e.g., for Dec 2025). This is highly anomalous and likely a major clerical error, questioning the document's validity.",{"company_name":64,"filing_date":92,"filing_source":58,"headline":97,"id":98,"stock_code":68,"summary_text":99},"CRISIL Reaffirms 'AAA\u002FStable' Rating, Citing Strong Promoter Support & Healthy Capitalization","69bff2efc1595024c2c3300f","- **Top-Tier Ratings Reaffirmed:** CRISIL has reaffirmed the company's highest long-term rating of `CRISIL AAA\u002FStable` and short-term rating of `CRISIL A1+`. A new `CRISIL AA+\u002FStable` rating was assigned to Perpetual Bonds worth ₹1,500 crore.\n- **Strong Performance & Turnaround:** The company demonstrated robust growth with Assets Under Management (AUM) reaching ₹55,017 crore. It reported a profit of ₹287 crore (9M FY26), a significant turnaround from a loss in the previous fiscal year.\n- **Key Strengths:** The ratings are anchored by strong promoter support from the Cyrus Poonawalla group, healthy capitalization (18.17% Capital Adequacy Ratio), and a diversified funding profile.\n- **Monitorables & Risks:** Key risks include managing asset quality as the rapidly grown loan book seasons and the impact of expansion costs on near-term profitability.\n- **Red Flag:** The filing is unusually dated March 20, 2026, which appears to be a clerical error.",{"company_name":64,"filing_date":92,"filing_source":58,"headline":101,"id":102,"stock_code":68,"summary_text":103},"CRISIL Reaffirms 'AAA\u002FStable' Rating on Strong Promoter Support & Capital","69bff329e2addc7744599980","*   CRISIL reaffirmed its highest long-term rating of \u003Cb>'CRISIL AAA\u002FStable'\u003C\u002Fb> on the company's bank facilities and debt instruments, and the highest short-term rating of \u003Cb>'CRISIL A1+'\u003C\u002Fb>.\n*   The rating is driven by strong promoter support from the Poonawalla group, healthy capitalization (Networth: ₹9,996 Cr), and a diversified funding mix.\n*   Assets Under Management (AUM) grew rapidly to \u003Cb>₹55,017 crore\u003C\u002Fb> as of Dec 2025, with a strategic focus on consumer and MSME financing.\n*   Key monitorables include managing asset quality in the fast-growing, unseasoned loan book and sustaining profitability amid expansion.\n*   🚨 \u003Cb>Red Flag:\u003C\u002Fb> The filing and all associated financial data are dated for the future (March 2026, FY25-26), which is highly unusual and raises questions about the document's reliability.",{"company_name":64,"filing_date":105,"filing_source":58,"headline":106,"id":107,"stock_code":68,"summary_text":108},"2026-03-21T00:52:11.620000","CARE Ratings Reaffirms 'AAA; Stable' Rating","69bff2e514f116b023204fa2","*   CARE Ratings has reaffirmed the company's long-term bank facilities and NCDs at 'CARE AAA; Stable', signifying the highest degree of safety. The outlook remains \"Stable\".\n*   A new rating of 'CARE AA+; Stable' has been assigned to Perpetual Debt instruments worth ₹1,500 crore.\n*   The company reported strong growth in Assets Under Management (AUM), reaching ₹55,017 crore as of Dec 2025 (9MFY26).\n*   Asset quality has improved, with Gross NPAs reducing to 1.51% after a temporary spike earlier in the year due to stress in a legacy loan book.\n*   \u003Cb>Note:\u003C\u002Fb> The filing is dated March 2026, which is highly unusual and likely a typographical error, as all financial data pertains to periods ending in FY24, FY25, and FY26.",{"company_name":64,"filing_date":105,"filing_source":58,"headline":110,"id":111,"stock_code":68,"summary_text":112},"Poonawalla Fincorp's 'AAA' Rating Reaffirmed; Promoter Infuses ₹1,500 Cr","69bff2f2cd586b864dc7b909","*   CARE Ratings has reaffirmed the company's top-tier long-term rating at 'CARE AAA; Stable' and short-term rating at 'CARE A1+', citing strong promoter support.\n*   The promoter group (Cyrus Poonawalla) infused an additional \u003Cb>₹1,500 crore\u003C\u002Fb> in equity, reinforcing the company's capital base.\n*   A new 'CARE AA+; Stable' rating was assigned to a new ₹1,500 crore Perpetual Debt instrument, facilitating further capital raising.\n*   \u003Cb>Key Red Flag:\u003C\u002Fb> The company reported a net loss of ₹98 crore in FY25, a significant downturn from the prior year's profit. Profitability has since recovered in the first nine months of FY26.\n*   \u003Cb>Asset Quality Concern:\u003C\u002Fb> Gross NPAs spiked to 2.10% in Q2FY25 due to stress in the personal loan book, but have since improved to 1.51% as of December 2025.",{"company_name":64,"filing_date":105,"filing_source":58,"headline":114,"id":115,"stock_code":68,"summary_text":116},"CARE Ratings Reaffirms 'AAA; Stable' Rating, Cites Strong Promoter Support","69bff32b13f0bdde0159989f","- \u003Cb>Credit Rating Reaffirmed:\u003C\u002Fb> CARE Ratings has reaffirmed the highest rating of 'CARE AAA; Stable' for long-term facilities and 'CARE A1+' for short-term instruments. A new Perpetual Debt instrument of ₹1,500 crore was also assigned a 'CARE AA+; Stable' rating.\n\n- \u003Cb>Strong AUM Growth:\u003C\u002Fb> Assets Under Management (AUM) grew significantly to ₹55,017 crore as of Dec 2025, with an aggressive target of 5x-6x growth over the next five years.\n\n- \u003Cb>Volatile Profitability (Red Flag):\u003C\u002Fb> The company reported a \u003Cb>net loss of ₹98 crore in FY25\u003C\u002Fb>, a sharp contrast to the one-off driven profit in FY24. However, profitability has since recovered in the first nine months of FY26.\n\n- \u003Cb>Key Risks to Monitor:\u003C\u002Fb> The rating agency noted a past spike in Gross NPAs (to 2.10% in Sep 2024) and an increase in gearing (to 4.34x) as key monitorables for the future.\n\n- \u003Cb>Strong Promoter Backing:\u003C\u002Fb> The rating is heavily supported by the Cyrus Poonawalla group, which has infused over ₹4,700 crore since 2021, providing significant comfort to stakeholders.",{"company_name":118,"filing_date":119,"filing_source":9,"headline":120,"id":121,"stock_code":68,"summary_text":122},"Poonawalla Fincorp Ltd","2026-03-21T00:52:11.304000","CARE Ratings Reaffirms 'AAA' Rating Amidst Aggressive Growth Plans","69bff2dc13f0bdde0159989d","• \u003Cb>Top Rating Reaffirmed:\u003C\u002Fb> CARE Ratings has reaffirmed its highest 'CARE AAA; Stable' rating for the company's long-term facilities, citing strong promoter support and healthy capitalisation. A new rating of 'CARE AA+; Stable' was assigned to a Perpetual Debt instrument.\n\n• \u003Cb>Aggressive Growth Target:\u003C\u002Fb> Management is aiming for a 5x-6x growth in Assets Under Management (AUM) from FY24 levels over the next five years, driven by new products and a 'phygital' expansion.\n\n• \u003Cb>Strong Promoter Backing:\u003C\u002Fb> The Cyrus Poonawalla group demonstrated strong commitment with a fresh equity infusion of ₹1,500 crore in September 2025.\n\n• \u003Cb>Key Monitorables:\u003C\u002Fb> The company reported a net loss of ₹98 crore in FY25, a sharp contrast to profits in FY24 and 9MFY26. While asset quality saw a temporary spike in Q2FY25, it has since improved, with Gross NPA at 1.51% as of Dec 2025.",{"company_name":118,"filing_date":119,"filing_source":9,"headline":124,"id":125,"stock_code":68,"summary_text":126},"Poonawalla Fincorp's Credit Rating Reaffirmed at 'CARE AAA; Stable'","69bff2f1b9faa4a752c33042","*   CARE Ratings has reaffirmed the company's long-term rating at \u003Cb>'CARE AAA; Stable'\u003C\u002Fb> and short-term rating at \u003Cb>'CARE A1+'\u003C\u002Fb>, signifying the highest degree of safety.\n*   A new rating of \u003Cb>'CARE AA+; Stable'\u003C\u002Fb> was assigned to a new Perpetual Debt instrument worth ₹1,500 crore.\n*   Assets Under Management (AUM) grew strongly to ₹55,017 crore as of Dec 2025. However, the company reported a net loss of ₹98 crore in FY25, following a year of high profit driven by exceptional gains.\n*   Asset quality has improved, with Gross NPA at 1.51% as of 9MFY26. This follows a previous spike caused by stress in the small ticket personal loan (STPL) book, which has since been addressed.\n*   Capitalization remains strong (CAR 18.17%), bolstered by a recent \u003Cb>promoter equity infusion of ₹1,500 crore\u003C\u002Fb> in Sep 2025.\n*   The company appointed a new MD & CEO, Mr. Arvind Kapil, in June 2024 and has an ambitious plan for 5x-6x AUM growth over the next five years.",{"company_name":118,"filing_date":119,"filing_source":9,"headline":128,"id":129,"stock_code":68,"summary_text":130},"CARE Reaffirms 'AAA' Rating, Citing Strong Promoter Support & Growth Outlook","69bff310d4af8cad3c204f48","• CARE Ratings has reaffirmed the highest credit rating of 'CARE AAA; Stable' for the company's long-term debt and 'CARE A1+' for its short-term instruments.\n• The company reported strong Assets Under Management (AUM) growth, reaching ₹55,017 crore as of Dec 2025, and is targeting 5x-6x growth over the next five years.\n• Despite a net loss of ₹98 crore in FY25, profitability has shown recovery in recent quarters. Asset quality has also improved after a spike related to a legacy loan book.\n• Promoters demonstrated strong backing with a recent equity infusion of ₹1,500 crore, bolstering the company's healthy capital adequacy ratio (18.17%).",{"company_name":132,"filing_date":133,"filing_source":58,"headline":134,"id":135,"stock_code":136,"summary_text":137},"Glenmark Pharmaceuticals Limited","2026-03-21T00:32:14.059000","Launches Affordable Semaglutide Drug GLIPIQ® in India","69bff2aa06cfb807e9c7b91c","GLENMARK","*   Announced the launch of GLIPIQ® (Semaglutide) in India for the management of Type 2 Diabetes.\n*   Aims to set a new benchmark in affordability, with the weekly cost of therapy starting at ₹325.\n*   The product has received approval from India's drug regulator (CDSCO) following a Phase III clinical trial.\n*   \u003Cb>Key Red Flag:\u003C\u002Fb> The filing is dated March 21, 2026, a future date that is a significant anomaly and likely an error.",{"company_name":64,"filing_date":139,"filing_source":58,"headline":140,"id":141,"stock_code":68,"summary_text":142},"2026-03-21T00:28:33.419000","CARE Reaffirms Highest 'AAA' Rating; Cites Strong Promoter Support & Growth","69bff2af30cad470bb204f45","*   \u003Cb>Top-Tier Rating Reaffirmed:\u003C\u002Fb> CARE Ratings has reaffirmed its highest credit rating of 'CARE AAA; Stable' for long-term facilities and 'CARE A1+' for short-term instruments, signaling maximum safety and creditworthiness.\n*   \u003Cb>Strong Promoter Support:\u003C\u002Fb> The rating is underpinned by unwavering support from the Cyrus Poonawalla group, highlighted by a recent capital infusion of ₹1,500 crore in September 2025.\n*   \u003Cb>Aggressive Growth & Performance:\u003C\u002Fb> Assets Under Management (AUM) have surged to ₹55,017 Crore. The company is targeting 5x-6x AUM growth over the next five years under its new leadership.\n*   \u003Cb>Key Risks to Monitor:\u003C\u002Fb> While the outlook is positive, key watchpoints include recent earnings volatility (a net loss in FY25), a temporary spike in NPAs in Q2FY25, and rising gearing (4.34x), which is approaching the rating agency's negative trigger of 5x.",{"company_name":64,"filing_date":139,"filing_source":58,"headline":144,"id":145,"stock_code":68,"summary_text":146},"CARE Reaffirms 'AAA' Rating Amidst Mixed Financials & New Fundraising","69bff2b6d4af8cad3c204f41","*   **Credit Rating:** CARE Ratings has reaffirmed the company's top-tier **'CARE AAA; Stable'** rating for its long-term bank facilities and **'CARE A1+'** for short-term instruments, citing strong promoter support.\n*   **FY25 Performance:** The company reported a **net loss of ₹98 crore for FY25 (Audited)**, a sharp reversal from the ₹2,056 crore profit in FY24 (which included a one-off gain from a subsidiary sale).\n*   **Asset Quality:** Gross NPA saw a temporary spike to 2.10% in Q2FY25 due to stress in an old loan book, but has since improved to 1.51% as of December 2025.\n*   **Capital & Fundraising:** Promoters infused **₹1,500 crore in equity** in September 2025. The company is also raising a new **₹1,500 crore Perpetual Debt** instrument, which has been assigned a 'CARE AA+; Stable' rating.",{"company_name":64,"filing_date":139,"filing_source":58,"headline":148,"id":149,"stock_code":68,"summary_text":150},"CARE Ratings Reaffirms Top-Tier 'AAA' Credit Rating","69bff2e4e2addc774459997e","*   CARE Ratings has reaffirmed the company's long-term rating at **'CARE AAA; Stable'** and short-term rating at **'CARE A1+'**. These are the highest possible ratings, indicating minimal credit risk.\n*   Key strengths cited include strong promoter support from the Cyrus Poonawalla group, a healthy capitalisation profile (bolstered by a recent ₹1,500 Cr promoter infusion), and a clear growth strategy under new leadership.\n*   The company demonstrated robust growth, with Assets Under Management (AUM) surging from ₹25,003 crore in FY24 to **₹55,017 crore** as of December 2025.\n*   The outlook is 'Stable', but key monitorables include maintaining asset quality while pursuing an ambitious target of 5x-6x AUM growth over the next five years.",{"company_name":64,"filing_date":152,"filing_source":58,"headline":153,"id":154,"stock_code":68,"summary_text":155},"2026-03-21T00:28:33.333000","CARE Ratings Reaffirms Top-Tier 'AAA' Rating","69bff2abcd586b864dc7b907","*   CARE Ratings has reaffirmed the company's highest long-term rating at \u003Cb>'CARE AAA; Stable'\u003C\u002Fb> and short-term rating at \u003Cb>'CARE A1+'\u003C\u002Fb>.\n*   A new rating of \u003Cb>'CARE AA+; Stable'\u003C\u002Fb> was assigned to the upcoming Perpetual Debt issue of ₹1,500 Crore.\n*   The company reported strong AUM growth, but recorded a \u003Cb>net loss of ₹98 Crore in FY25\u003C\u002Fb> before recovering to a PAT of ₹287 Cr in 9MFY26.\n*   Promoters showed strong support by infusing \u003Cb>₹1,500 Crore in equity\u003C\u002Fb> via a preferential issue.\n*   Asset quality, which saw Gross NPA spike to 1.84% in FY25, has since improved to \u003Cb>1.51% in 9MFY26\u003C\u002Fb>.\n*   \u003Cb>Note:\u003C\u002Fb> The filing contains futuristic dates (2025, 2026), which are likely typographical errors but reported as per the source.",{"company_name":64,"filing_date":152,"filing_source":58,"headline":157,"id":158,"stock_code":68,"summary_text":159},"CARE Ratings Reaffirms 'AAA; Stable' Rating, Highlighting Strong Growth & Promoter Backing","69bff2b3e2d5e830b1c7b96d","• CARE Ratings has reaffirmed the company's highest long-term rating of 'CARE AAA; Stable' and short-term rating of 'CARE A1+'. A new rating of 'CARE AA+; Stable' was also assigned to Perpetual Debt of ₹1,500 crore.\n• The rating is underpinned by strong promoter support from the Cyrus Poonawalla group, highlighted by a recent capital infusion of nearly ₹1,500 crore in September 2025.\n• The company demonstrated robust AUM growth, reaching ₹55,017 crore as of Dec 2025, and is targeting 5x-6x growth over the next five years under its new leadership.\n• Asset quality has improved, with Gross NPA at 1.51% as of Dec 2025, supported by a revised product strategy and a strengthened management team.",{"company_name":64,"filing_date":152,"filing_source":58,"headline":161,"id":162,"stock_code":68,"summary_text":163},"CARE Reaffirms 'AAA' Rating Amidst Strategic Pivot & FY25 Loss","69bff2ea06cfb807e9c7b91e","*   **Credit Rating:** CARE Ratings reaffirmed its highest 'CARE AAA; Stable' rating for long-term debt but assigned a new 'CARE AA+; Stable' rating to ₹1,500 Crore of Perpetual Debt.\n*   **Financial Performance:** The company reported a net loss of ₹-98 Crore for the fiscal year ending March 31, 2025, a material negative development.\n*   **Asset Quality:** Gross NPAs spiked to 2.10% during FY25 due to stress in a legacy loan book but have since improved to 1.51% as of December 2025.\n*   **Promoter Support:** Promoters infused ₹1,500 Crore in equity in September 2025, reinforcing their support for the new strategy under CEO Mr. Arvind Kapil, who joined in June 2024.\n*   \u003Cb>Red Flag:\u003C\u002Fb> The filing is dated March 20, 2026, and reports on financial data for future periods (e.g., FY25, Dec 2025). This is a significant anomaly, suggesting the dates are erroneous or hypothetical.",{"company_name":132,"filing_date":165,"filing_source":58,"headline":166,"id":167,"stock_code":136,"summary_text":168},"2026-03-21T00:28:33.309000","Launches Affordable Semaglutide Drug GLIPIQ® to Target India's Diabetes Market","69bff29e14f116b023204fa0","*   Announced the launch of GLIPIQ® (Semaglutide) in India for the management of Type 2 Diabetes.\n*   The drug is strategically priced to be highly affordable, with a weekly treatment cost starting at ₹325, aiming to set a \"new benchmark in affordability\" for GLP-1 therapy.\n*   This launch is a key strategic initiative to penetrate the high-growth diabetes market in India and is positioned as a significant potential revenue driver for the company.\n*   GLIPIQ® has been approved by the Central Drugs Standard Control Organization (CDSCO) in India following a successful Phase III clinical study.\n*   The company is also introducing 'Sankalp', a patient support program, to improve therapy initiation and long-term adherence.",{"company_name":132,"filing_date":165,"filing_source":58,"headline":170,"id":171,"stock_code":136,"summary_text":172},"Glenmark Disrupts Diabetes Market with Low-Cost Semaglutide Launch","69bff2a6cd947ce0af5998fa","*   Glenmark has launched GLIPIQ® (semaglutide) in India for the management of Type 2 Diabetes.\n*   The drug is priced disruptively, with a weekly treatment cost starting at ₹325, aiming to make advanced diabetes therapy more affordable.\n*   The launch is supported by a new patient support program, 'Sankalp', to improve therapy adherence.\n*   GLIPIQ® has received approval from India's drug regulator (CDSCO) after a successful Phase III clinical trial.\n*   \u003Cb>Red Flag:\u003C\u002Fb> The filing is dated March 21, 2026, a future date, which is highly unusual and likely an error.",{"company_name":174,"filing_date":175,"filing_source":9,"headline":176,"id":177,"stock_code":136,"summary_text":178},"Glenmark Pharmaceuticals Ltd","2026-03-21T00:28:32.989000","Launches Affordable Diabetes Drug GLIPIQ® in India","69bff29fc1595024c2c3300d","*   Glenmark has launched **GLIPIQ® (Semaglutide)** in India for the management of Type 2 Diabetes.\n*   The company is setting a **new benchmark in affordability** for advanced diabetes therapy, with weekly treatment starting at ₹325.\n*   This strategic launch aims to penetrate the high-growth GLP-1 therapy market by significantly lowering the cost barrier for patients.\n*   The product has been approved by the **Central Drugs Standard Control Organization (CDSCO)** following a successful Phase III clinical trial in India.\n*   **Red Flag:** The filing was dated for the future (**March 21, 2026**), which is an unusual detail noted in the analysis.",{"company_name":118,"filing_date":180,"filing_source":9,"headline":181,"id":182,"stock_code":68,"summary_text":183},"2026-03-21T00:28:32.979000","CARE Reaffirms 'AAA' Rating Amidst FY25 Loss & Strong Growth Outlook","69bff2aab9faa4a752c3303f","*   \u003Cb>Rating Reaffirmed:\u003C\u002Fb> CARE Ratings has reaffirmed the company's long-term rating at \u003Cb>'CARE AAA; Stable'\u003C\u002Fb>, citing strong promoter support from the Cyrus Poonawalla group.\n*   \u003Cb>FY25 Financials:\u003C\u002Fb> The company reported a \u003Cb>net loss of ₹98 crore for FY25\u003C\u002Fb>, a sharp contrast to the prior year's profit. However, Assets Under Management (AUM) grew significantly to ₹55,017 crore as of Dec 2025.\n*   \u003Cb>Asset Quality:\u003C\u002Fb> Gross NPAs spiked temporarily in Q2FY25 due to stress in a legacy loan book but have since improved, reducing to 1.51% as of Dec 2025.\n*   \u003Cb>Promoter Support:\u003C\u002Fb> Promoters infused \u003Cb>₹1,500 crore in equity\u003C\u002Fb> in September 2025, reinforcing their commitment and strengthening the balance sheet.\n*   \u003Cb>Leadership & Strategy:\u003C\u002Fb> Mr. Arvind Kapil was appointed as the new MD & CEO in June 2024. The company is targeting \u003Cb>5x-6x AUM growth\u003C\u002Fb> over the next five years.",{"company_name":118,"filing_date":180,"filing_source":9,"headline":185,"id":186,"stock_code":68,"summary_text":187},"CARE Ratings Reaffirms 'AAA' Rating, Assigns 'AA+' to New Debt","69bff2ae955551b9b1c33037","*   **Rating Reaffirmed:** CARE Ratings has reaffirmed its highest 'CARE AAA; Stable' rating for the company's Long-term Bank Facilities (₹27,520 Cr) and NCDs, and 'CARE A1+' for its Commercial Paper (₹7,500 Cr).\n*   **New Rating Assigned:** A new rating of 'CARE AA+; Stable' has been assigned to the company's Perpetual Debt instrument amounting to ₹1,500 Crore.\n*   **Key Strengths:** The high rating is supported by strong promoter backing from the Cyrus Poonawalla group, including a recent capital infusion of ₹1,500 crore, and healthy capitalization.\n*   **Performance & Growth:** The company continues its strong growth trajectory, with Assets Under Management (AUM) reaching ₹55,017 crore. Management is targeting 5x-6x AUM growth over the next five years.\n*   **Asset Quality:** Gross NPAs have improved to 1.51% as of Dec 2025, recovering from a temporary spike in Q2FY25 caused by stress in the erstwhile small-ticket personal loan portfolio.",{"company_name":118,"filing_date":180,"filing_source":9,"headline":189,"id":190,"stock_code":68,"summary_text":191},"CARE Ratings Reaffirms 'AAA; Stable' Rating, Citing Strong Promoter Support","69bff2e8cd947ce0af5998fc","• \u003Cb>Top-Tier Rating Reaffirmed:\u003C\u002Fb> CARE Ratings has reaffirmed its highest long-term rating of 'CARE AAA; Stable' on the company's bank facilities and debt instruments, and 'CARE A1+' on its Commercial Paper.\n• \u003Cb>Strong Promoter Backing:\u003C\u002Fb> The rating is driven by strong support from the Cyrus Poonawalla group, reinforced by a recent ₹1,500 crore equity infusion in September 2025.\n• \u003Cb>Performance Snapshot:\u003C\u002Fb> Assets Under Management (AUM) showed robust growth to ₹55,017 Cr. However, the company faced a temporary asset quality dip and a net loss in FY25, which are now showing signs of recovery.\n• \u003Cb>Growth Strategy:\u003C\u002Fb> A new management team is in place, targeting 5x-6x AUM growth over five years, driven by a 'phygital' model and six new loan products.\n• \u003Cb>Unusual Dating:\u003C\u002Fb> Please note, the filing and all associated dates (2025-2026) are set in the future, which is highly irregular and likely a data error in the source document.",{"company_name":193,"filing_date":194,"filing_source":9,"headline":195,"id":196,"stock_code":197,"summary_text":198},"Innovassynth Technologies (India) Ltd","2026-03-21T00:02:15.378000","New Website Live After Merger & Name Change","69bff26ae2addc7744599964","533315","*   The company has changed its official website to \u003Cb>www.innovassynth.com\u003C\u002Fb> as a result of a major corporate restructuring.\n*   The restructuring involved a \u003Cb>merger\u003C\u002Fb> and a subsequent \u003Cb>name change\u003C\u002Fb> from \"Innovassynth Investments Limited\" to \"Innovassynth Technologies (India) Limited\".\n*   \u003Cb>Red Flag:\u003C\u002Fb> This filing confirms a completed merger but lacks crucial details (e.g., share exchange ratios, effective dates). Investors should seek the full \"Scheme of Merger\" filing for a complete understanding.",{"company_name":193,"filing_date":194,"filing_source":9,"headline":200,"id":201,"stock_code":197,"summary_text":202},"New Website Live After Corporate Name Change & Merger","69bff277c1595024c2c3300b","*   The company has launched a new official website: \u003Cb>www.innovassynth.com\u003C\u002Fb>, replacing the old one.\n*   This follows a significant corporate restructuring through a \"Scheme of Merger by Absorption\".\n*   As a result of the merger, the company's name has been changed from \"Innovassynth Investments Limited\".\n*   \u003Cb>Key takeaway for investors:\u003C\u002Fb> The merger is a material event. Investors should seek further disclosures regarding its terms and impact.",{"company_name":193,"filing_date":194,"filing_source":9,"headline":204,"id":205,"stock_code":197,"summary_text":206},"Announces Name Change & New Website Following Merger","69bff27cd4af8cad3c204f3f","*   The company has officially changed its name from **Innovassynth Investments Limited** to **Innovassynth Technologies (India) Limited**.\n*   This follows a merger by absorption, transforming the company from an investment firm into an operating technology entity.\n*   This is a highly material development for shareholders, as it fundamentally changes the business profile and investment basis of the company.\n*   The company has launched a new website to reflect its new identity: `www.innovassynth.com`.",false,100,10,941]